Comparison of device-specific adverse event profiles between Impella platforms.

Stacey ChenDarien PaoneLilly SpellmanNeel K RanganathJulius A CarilloClaudia G GideaAlex ReyentovichCraig A ThompsonLouai RazzoukZachary N KonNader MoazamiDeane E Smith

Published in: Journal of cardiac surgery (2020)

This study suggests that for patients who require temporary MCS for more than 24 h, the Impella 5.0/LD may have a more favorable device-specific adverse profile compared with the Impella CP.

Keyphrases

extracorporeal membrane oxygenation
left ventricular assist device
emergency department
adverse drug